Citius Pharmaceuticals, Inc.

CTXR

$0.58

+1.83%

N/A+$0.01

Healthcare

Biotechnology

NASDAQ

Active Trading

Citius Pharmaceuticals, Inc. operates as a specialized pharmaceutical firm concentrating on the development and market introduction of critical care products. Its efforts ...

Key Metrics of CTXR

Snapshot

Latest / TTM · 6 periods

Market Cap

$6.48M

ROCE

-67.7%

EV / EBITDA

0.06x

-23.0% YoY

FCF Yield

-538.4%

-344.9% YoY

Cash Conversion Cycle

971.7d

Current Ratio

0.84

Quick take

TTM —

Current ratio below 1.0

Negative working capital

Key Metrics

Latest / TTM · 6 periods

Valuation trend

Valuation trend table

Metric	2021	2022	2023	2024	2025	TTM
Market CapTotal market value of all shares outstanding.	$220.46M	$176.76M	$103.55M	$145.11M	$13.72M	$6.48M
Enterprise ValueCompany value including debt and cash adjustments.	$151.24M	$135.73M	$77.55M	$142.12M	$11.28M	$-3.35M
EV / SalesHow many dollars investors pay per dollar of sales.	0.00x	0.00x	0.00x	0.00x	0.00x	-0.47x
EV / EBITDAValuation multiple versus operating earnings before non-cash charges.	-6.47x	-4.10x	-2.12x	-3.68x	-0.30x	0.06x
Net Debt / EBITDALeverage ratio using net debt divided by EBITDA.	2.96	1.24	0.71	0.08	0.06	0.17

Returns + ROCE gauge

ROCE latest

-67.7%

Prev year -44.8%

Returns + ROCE gauge table

Metric	2021	2022	2023	2024	2025	TTM
ROEProfit generated from shareholders' equity.	-17.4%	-32.7%	-35.8%	-55.9%	-55.4%	-67.1%
ROAProfit generated from total assets.	-16.2%	-29.5%	-31.4%	-33.6%	-28.6%	-32.5%
ROICReturn generated on invested operating capital.	-17.0%	-31.0%	-38.2%	-48.8%	-45.9%	-67.9%
ROCEOperating return on long-term capital used.	-17.0%	-30.4%	-37.5%	-52.0%	-44.8%	-67.7%
Earnings YieldEarnings as a percentage of market value.	-10.5%	-19.0%	-31.4%	-27.0%	-272.8%	-305.1%

Cash flow quality

Cash flow quality table

Metric	2021	2022	2023	2024	2025	TTM
FCFFCash flow available to all capital providers.	$-64.25M	$-28.36M	$-29.06M	$-28.20M	$-32.03M	$-42.52M
FCFECash flow available to equity holders after debt flows.	$-64.43M	$-28.36M	$-29.06M	$-28.20M	$-31.30M	$-35.58M
FCF YieldFree cash flow divided by market capitalization.	-29.1%	-16.0%	-28.1%	-19.4%	-193.5%	-538.4%
Income QualityHow well accounting earnings are backed by cash flow.	1.05	0.84	0.89	0.72	0.67	0.63
Capex / OCFShare of operating cash flow spent on capital expenditures.	-165.0%	0.0%	0.0%	0.0%	0.0%	-0.0%

Operating efficiency

Operating efficiency table

Metric	2021	2022	2023	2024	2025	TTM
DSOAverage days to collect cash from customers.	0.0d	0.0d	0.0d	0.0d	0.0d	35.3d
DIOAverage days inventory stays before being sold.	0.0d	0.0d	0.0d	14398.6d	37968.0d	1452.4d
DPOAverage days the company takes to pay suppliers.	2827.4d	0.0d	0.0d	8579.9d	23328.8d	516.0d
Operating CycleTime from buying inventory to collecting receivables.	0.0d	0.0d	0.0d	14398.6d	37968.0d	1487.7d
Cash Conversion CycleNet days cash is tied in operations.	-2827.4d	0.0d	0.0d	5818.7d	14639.2d	971.7d

Snapshot

Latest / TTM: —

Market Cap

$6.48M

ROE

-67.1%

FCF Yield

-538.4%

Current Ratio

0.84

Upstream

Confidential CDMO(s) – LYMPHIR Commercial ManufacturingEisai Co., Ltd.TSE:4523Confidential CMOs (x2) – Mino-Lok ManufacturingAlpex Pharma S.A.Novel Anti-Infective Technologies, LLC (NAT)Novellus Therapeutics (now Ernexa Therapeutics Inc.)NASDAQ:ERNA

Downstream

McKesson CorporationNYSE:MCK Cardinal Health, Inc.NYSE:CAH Cencora, Inc. (formerly AmerisourceBergen)NYSE:CORUniphar plcISE:UPRIntegris Pharma S.A.Er-Kim Pharmaceuticals

Proxies

Citius Oncology, Inc.NASDAQ:CTOREisai Co., Ltd.TSE:4523McKesson CorporationNYSE:MCK

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer

No matching stocks found

Citius Pharmaceuticals, Inc.

Key Metrics of CTXR

Key Metrics

Valuation trend

Returns + ROCE gauge

Cash flow quality

Operating efficiency

Snapshot

Supply Chain of CTXR

Upstream

Downstream

Proxies

Key Metrics of CTXR

Key Metrics

Valuation trend

Returns + ROCE gauge

Cash flow quality

Operating efficiency

Snapshot

Supply Chain of CTXR

Upstream

Downstream

Proxies